ES2170050T3 - Metodos y composiciones para inducir la ereccion. - Google Patents
Metodos y composiciones para inducir la ereccion.Info
- Publication number
- ES2170050T3 ES2170050T3 ES90914620T ES90914620T ES2170050T3 ES 2170050 T3 ES2170050 T3 ES 2170050T3 ES 90914620 T ES90914620 T ES 90914620T ES 90914620 T ES90914620 T ES 90914620T ES 2170050 T3 ES2170050 T3 ES 2170050T3
- Authority
- ES
- Spain
- Prior art keywords
- terminal
- man
- impotence
- injection
- histidine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000000203 mixture Substances 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 4
- 201000001881 impotence Diseases 0.000 abstract 4
- 238000002347 injection Methods 0.000 abstract 4
- 239000007924 injection Substances 0.000 abstract 4
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 3
- 239000000674 adrenergic antagonist Substances 0.000 abstract 2
- 230000001272 neurogenic effect Effects 0.000 abstract 2
- 230000035515 penetration Effects 0.000 abstract 2
- 101500027321 Homo sapiens N-terminal peptide Proteins 0.000 abstract 1
- 101500027956 Homo sapiens Vasoactive intestinal peptide Proteins 0.000 abstract 1
- 206010049976 Impatience Diseases 0.000 abstract 1
- 102000055135 Vasoactive Intestinal Peptide Human genes 0.000 abstract 1
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- VBUWHHLIZKOSMS-RIWXPGAOSA-N invicorp Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)C(C)C)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=C(O)C=C1 VBUWHHLIZKOSMS-RIWXPGAOSA-N 0.000 abstract 1
- 210000003899 penis Anatomy 0.000 abstract 1
- IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
- Load-Engaging Elements For Cranes (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
- Revetment (AREA)
- Meat, Egg Or Seafood Products (AREA)
- Detergent Compositions (AREA)
Abstract
ESTA INVENCION PROPORCIONA METODOS Y COMPOSICIONES PARA INDUCIR A UN HOMBRE QUE SUFRE DE IMPOTENCIA, ERECCIONES DEL PENE SUFICIENTES PARA LA PENETRACION VAGINAL. CUANDO LA IMPOTENCIA SOLO ES SUSTANCIALMENTE NEUROGENICA SICOGENICA O NEUROGENICA Y SICOGENICA, UN METODO DE LA INVENCION COMPRENDE (A) ADMINISTRAR AL HOMBRE MEDIANTE UNA INYECCION INTRACAVERNOSA PEPTIDO N-TERMINAL HISTIDINA C-TERMINAL METIONINEAMIDA Y (B) ESTIMULAR AL HOMBRE SEXUALMENTE. CUANDO LA IMPOTENCIA ESTA CAUSADA POR UNA ARTEROESCLEROSIS SEVERA, UN METODO DE LA INVENCION COMPRENDE (A) ADMINISTRAR AL HOMBRE MEDIANTE UNA INYECCION INTRACAVERNOSA UNA CANTIDAD DE UNA COMPOSICION FISIOLOGICAMENTE ACEPTABLE QUE COMPRENDE (I) UN NEUROPEPTIDO SELECCIONADO DEL GRUPO QUE CONSISTE EN PEPTIDO INTESTINAL VASOACTIVO HUMANO Y PEPTIDO N-TERMINAL HISTIDINE C-TERMINAL METIONINEAMIDA Y (2) UN BLOQUEADOR ALFA-ADRENERGICO, TAL COMO FEUTOLAMINA O PRAZOSINA, Y (B) ESTIMULAR SEXUALMENTE AL HOMBRE. LA INVENCION INCLUYE TAMBIEN UNA COMPOSICION FISIOLOGICAMENTE ACEPTABLE APROPIADA PARA UTILIZAR EN LA INDUCCION, DESPUES DE LA ADMINISTRACION A UN HOMBRE QUE SUFRE DE IMPOTENCIA INYECCION INTRACAVERNOSA, DE UNA ERECCION, SUFICIENTE PARA LA PENETRACION VAGINAL, CUANDO LA IMPOTENCIA ES OCASIONADA POR UNA SEVERA ARTEROESCLEROSIS, CUYA COMPOSICION COMPRENDE (I) UN NEUROPEPTIDO SELECCIONADO DEL GRUPO QUE CONSISTE EN PEPTIDO INTESTINAL VASOACTIVO Y PEPTIDO N-TERMINAL HISTIDINA C-TERMINAL METIONINEAMIDA Y (2) UN BLOQUEADOR ALFA-ADRENERGICO, TAL COMO FEUTOLAMINA O PAROSINA.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/408,754 US5236904A (en) | 1989-09-18 | 1989-09-18 | Erection-inducing methods and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2170050T3 true ES2170050T3 (es) | 2002-08-01 |
Family
ID=23617626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES90914620T Expired - Lifetime ES2170050T3 (es) | 1989-09-18 | 1990-09-14 | Metodos y composiciones para inducir la ereccion. |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US5236904A (es) |
| EP (1) | EP0493485B1 (es) |
| JP (1) | JP3149946B2 (es) |
| KR (1) | KR100230720B1 (es) |
| AT (1) | ATE210994T1 (es) |
| AU (1) | AU641184B2 (es) |
| BR (1) | BR9007662A (es) |
| CA (1) | CA2065270C (es) |
| CZ (1) | CZ280446B6 (es) |
| DE (1) | DE69033881T2 (es) |
| DK (1) | DK0493485T3 (es) |
| ES (1) | ES2170050T3 (es) |
| FI (1) | FI104231B (es) |
| GE (1) | GEP19981264B (es) |
| HU (1) | HU208088B (es) |
| IL (1) | IL95505A (es) |
| LT (1) | LT3544B (es) |
| LV (1) | LV10198B (es) |
| NO (1) | NO307498B1 (es) |
| RO (1) | RO116346B1 (es) |
| RU (1) | RU2098120C1 (es) |
| SK (1) | SK452490A3 (es) |
| WO (1) | WO1991004039A1 (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5447912A (en) * | 1989-09-18 | 1995-09-05 | Senetek, Plc | Erection-inducing methods and compositions |
| US5242391A (en) * | 1990-04-25 | 1993-09-07 | Alza Corporation | Urethral insert for treatment of erectile dysfunction |
| DE4117249C2 (de) * | 1991-05-27 | 1998-05-14 | Christian Dr Stief | Linsidomin zur Behandlung erektiler Dysfunktionen |
| US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
| US5482039A (en) * | 1994-03-25 | 1996-01-09 | Vivus, Inc. | Process for diagnosing erectile dysfunction, and related methods of treatment |
| US5583144A (en) * | 1995-02-24 | 1996-12-10 | Kral; John G. | Methods for treating erectile impotence |
| US5731339A (en) * | 1995-04-28 | 1998-03-24 | Zonagen, Inc. | Methods and formulations for modulating the human sexual response |
| US5994294A (en) * | 1996-02-02 | 1999-11-30 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| US5932538A (en) * | 1996-02-02 | 1999-08-03 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses |
| US6294517B1 (en) | 1996-02-02 | 2001-09-25 | Nitromed, Inc. | Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use |
| US20020143007A1 (en) * | 1996-02-02 | 2002-10-03 | Garvey David S. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use |
| US20050065161A1 (en) * | 1996-02-02 | 2005-03-24 | Nitromed, Inc. | Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses |
| US6323211B1 (en) | 1996-02-02 | 2001-11-27 | Nitromed, Inc. | Compositions and methods for treating sexual dysfunctions |
| US6469065B1 (en) | 1996-02-02 | 2002-10-22 | Nitromed, Inc. | Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use |
| US20030004170A1 (en) * | 1997-05-19 | 2003-01-02 | Zonagen, Inc. | Combination therapy for modulating the human sexual response |
| US5947901A (en) * | 1997-09-09 | 1999-09-07 | Redano; Richard T. | Method for hemodynamic stimulation and monitoring |
| US5942545A (en) * | 1998-06-15 | 1999-08-24 | Macrochem Corporation | Composition and method for treating penile erectile dysfunction |
| US6011043A (en) * | 1998-06-19 | 2000-01-04 | Schering Corporation | Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction |
| US6482426B1 (en) * | 1998-09-17 | 2002-11-19 | Zonagen, Inc. | Compositions for the treatment of male erectile dysfunction |
| US6706682B2 (en) * | 1999-01-21 | 2004-03-16 | The Trustees Of Columbia University In The City Of New York | Uses of vascular endothelial growth factor in the treatment of erectile dysfunction |
| US6730065B1 (en) * | 2000-09-15 | 2004-05-04 | Ocularis Pharma, Inc. | Night vision composition |
| US6211156B1 (en) * | 1999-11-10 | 2001-04-03 | Asta Medica A.G. | Peptides for treatment of erectile dysfunction |
| US6650943B1 (en) | 2000-04-07 | 2003-11-18 | Advanced Bionics Corporation | Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction |
| AU2001259848B2 (en) * | 2000-05-12 | 2005-10-13 | Septodont Holding Sas | Local anesthetic methods and kits |
| US20060211753A1 (en) * | 2000-11-03 | 2006-09-21 | Ocularis Pharma, Inc. | Method and composition which reduces stimulation of muscles which dilate the eye |
| US6885895B1 (en) * | 2001-04-26 | 2005-04-26 | Advanced Bionics Corporation | Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction |
| US8178489B2 (en) * | 2005-03-07 | 2012-05-15 | Mondobiotech Ag | Formulation for aviptadil |
| US20130172274A1 (en) | 2005-12-20 | 2013-07-04 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| EP1971355B1 (en) | 2005-12-20 | 2020-03-11 | Duke University | Methods and compositions for delivering active agents with enhanced pharmacological properties |
| US8841255B2 (en) | 2005-12-20 | 2014-09-23 | Duke University | Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides |
| JP2011526303A (ja) | 2008-06-27 | 2011-10-06 | デューク ユニバーシティ | エラスチン様ペプチドを含む治療剤 |
| MX366935B (es) | 2009-08-14 | 2019-07-31 | Phasebio Pharmaceuticals Inc | Peptidos intestinales vasoactivos modificados. |
| EP2493434A1 (en) | 2009-10-30 | 2012-09-05 | Medispec Ltd | Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves |
| US9561262B2 (en) | 2011-06-06 | 2017-02-07 | Phasebio Pharmaceuticals, Inc. | Use of modified vasoactive intestinal peptides in the treatment of hypertension |
| GB201221032D0 (en) * | 2012-11-22 | 2013-01-09 | Mens Health Ltd | Method of treatment |
| GB201221046D0 (en) * | 2012-11-22 | 2013-01-09 | Mens Health Ltd | Method of diagnosis |
| EP3139949B1 (en) | 2014-05-08 | 2020-07-29 | Phasebio Pharmaceuticals, Inc. | Compositions comprising a vip-elp fusion protein for use in treating cystic fibrosis |
| WO2016130518A2 (en) | 2015-02-09 | 2016-08-18 | Phasebio Pharmaceuticals, Inc. | Methods and compositions for treating muscle disease and disorders |
| WO2019102310A1 (en) | 2017-11-24 | 2019-05-31 | Alaval (Pty) Ltd | Vip formulation for management of inflammatory conditions |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3898329A (en) * | 1971-09-17 | 1975-08-05 | Sami I Said | Vasoactive intestinal peptide, composition and method |
| DE3637157A1 (de) * | 1985-11-01 | 1987-05-21 | Byk Gulden Lomberg Chem Fab | Arzneimittel zur behandlung erektiler dysfunktionen |
| JPS62246595A (ja) * | 1986-04-17 | 1987-10-27 | Eisai Co Ltd | 気菅支拡張作用・降圧作用ペプタイド |
| US4939224A (en) * | 1987-02-26 | 1990-07-03 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Vasoactive intestinal peptide analogs |
| IL87055A (en) * | 1988-07-08 | 1994-06-24 | Illana Gozes | Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them |
| SE463851B (sv) * | 1988-09-02 | 1991-02-04 | Amsu Ltd | Komposition foer behandling av erektil dysfunktion via uretra |
-
1989
- 1989-09-18 US US07/408,754 patent/US5236904A/en not_active Expired - Lifetime
-
1990
- 1990-08-28 IL IL95505A patent/IL95505A/xx active IP Right Grant
- 1990-09-14 RO RO92-200339A patent/RO116346B1/ro unknown
- 1990-09-14 EP EP90914620A patent/EP0493485B1/en not_active Expired - Lifetime
- 1990-09-14 AT AT90914620T patent/ATE210994T1/de not_active IP Right Cessation
- 1990-09-14 ES ES90914620T patent/ES2170050T3/es not_active Expired - Lifetime
- 1990-09-14 RU SU925011648A patent/RU2098120C1/ru active
- 1990-09-14 WO PCT/US1990/005237 patent/WO1991004039A1/en not_active Ceased
- 1990-09-14 DE DE69033881T patent/DE69033881T2/de not_active Expired - Lifetime
- 1990-09-14 CA CA002065270A patent/CA2065270C/en not_active Expired - Lifetime
- 1990-09-14 AU AU64404/90A patent/AU641184B2/en not_active Expired
- 1990-09-14 HU HU92874A patent/HU208088B/hu unknown
- 1990-09-14 JP JP51377290A patent/JP3149946B2/ja not_active Expired - Lifetime
- 1990-09-14 DK DK90914620T patent/DK0493485T3/da active
- 1990-09-14 BR BR909007662A patent/BR9007662A/pt not_active Application Discontinuation
- 1990-09-17 SK SK4524-90A patent/SK452490A3/sk not_active IP Right Cessation
- 1990-09-17 CZ CS904524A patent/CZ280446B6/cs not_active IP Right Cessation
-
1992
- 1992-03-09 NO NO920915A patent/NO307498B1/no not_active IP Right Cessation
- 1992-03-10 KR KR1019920700543A patent/KR100230720B1/ko not_active Expired - Lifetime
- 1992-03-17 FI FI921136A patent/FI104231B/fi active
-
1993
- 1993-06-29 LV LVP-93-740A patent/LV10198B/lv unknown
- 1993-08-25 GE GEAP19931497A patent/GEP19981264B/en unknown
- 1993-12-10 LT LTIP1579A patent/LT3544B/lt not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2170050T3 (es) | Metodos y composiciones para inducir la ereccion. | |
| Waldhauser et al. | Efficiency and side effects of prostaglandin El in the treatment of erectile dysfunction | |
| CRONIN et al. | Human pancreatic tumor growth hormone (GH)-releasing factor and cyclic adenosine 3′, 5′-monophosphate evoke GH release from anterior pituitary cells: the effects of pertussis toxin, cholera toxin, forskolin, and cycloheximide | |
| EA199700213A1 (ru) | Крем на водной основе для локального применения, способ его приготовления, способ лечения эректильной дисфункции у мужчин, способ лечения аноргазма у женщин, способ лечения микроваскулярных заболеваний и способ лечения ран или хирургических рассечений | |
| ECSP014065A (es) | Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfuncion cognitiva en un mamifero | |
| NZ511131A (en) | Estrogen agonists/antagonists and cGMP elevators for treating female sexual dysfunction | |
| ES2190472T3 (es) | Parche transdermico para la administracion de 17-deacetil norgestimato, solo o en combinacion con un estrogeno. | |
| MY121276A (en) | Use of glp-1 or analogs to abolish catabolic changes after surgery | |
| DE69332713D1 (de) | Verwendung von Histamine-2 Agonisten zur Behandlung sexueller Funktionsstörungen | |
| Casentini et al. | Studies on the control of corticotrophin release | |
| Schally et al. | Alteration of LH and FSH release in rats treated with clomiphene or its isomers | |
| AU625561B2 (en) | Method and composition for preventing conception | |
| AR036970A1 (es) | Composicion farmaceutica androgenica y metodo para el tratamiento de la depresion | |
| IT9009007A1 (it) | 2, 4-diamino-6 piperidino pirimidina-3 ossido topico sul glande nel trattamento delle impotenze erettili | |
| Benkert et al. | Sexual impotence: a double-blind study of LHRH nasal spray versus placebo | |
| BRPI0409571A (pt) | métodos e kits para a manutenção de gravidez, tratamento de cistos foliculares, e sincronização da ovulação empregando-se hormÈnio de luteinização | |
| Sebastian et al. | Effects of progesterone pretreatment and duration of ram exposure on synchronization of estrus, conception and pregnancy by prostaglandin during seasonal anestrus | |
| DE69131629D1 (de) | Behandlung fehlender milchabsonderung beim menschen | |
| CA1294873C (en) | Method of regulating animal reproduction | |
| McCann | Saga of the discovery of hypothalamic releasing and inhibiting hormones | |
| Redding et al. | Depletion of pituitary thyrotropic hormone by thyrotropin releasing factor | |
| ATE307144T1 (de) | Vip-verwandte peptide zur behandlung von sexuellen funktionsstörungen bei frauen | |
| EP0484429B1 (en) | Method of treating infertility or sub-fertility in adult men, and the use of preparations in the method. | |
| McCann | In search of hypothalamic hormones | |
| KR920700675A (ko) | 발기 기능장해 치료용 약물(칼시토닌 유전자 관련 펩티드) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 493485 Country of ref document: ES |